Osteoprotegerin Gene as a Biomarker in the Development of Osteoporosis in Postmenopausal Women
Osteoporosis is a multifactorial and polygenic disease caused by an imbalance between osteoclastogenesis and osteoblastogenesis, leading to a decrease in bone mineral density and the occurrence of disorders in the microarchitecture and metabolism of bone tissue. In postmenopausal women, there is a s...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/12/3218 |
| _version_ | 1797381937966350336 |
|---|---|
| author | Filip Przerwa Izabela Uzar Anna Bogacz Katarzyna Kotrych Tadeusz Sulikowski Marlena Wolek Adam Kamiński Paweł Ziętek Bogusław Czerny |
| author_facet | Filip Przerwa Izabela Uzar Anna Bogacz Katarzyna Kotrych Tadeusz Sulikowski Marlena Wolek Adam Kamiński Paweł Ziętek Bogusław Czerny |
| author_sort | Filip Przerwa |
| collection | DOAJ |
| description | Osteoporosis is a multifactorial and polygenic disease caused by an imbalance between osteoclastogenesis and osteoblastogenesis, leading to a decrease in bone mineral density and the occurrence of disorders in the microarchitecture and metabolism of bone tissue. In postmenopausal women, there is a significant decrease in the production of estrogens, which play a key role in maintaining proper bone mineral density. Estrogens have an inhibitory effect on the development and activity of osteoclasts by reducing the synthesis of pro-resorption cytokines and stimulating the expression of osteoprotegerin (OPG). Osteoprotegerin is a cytokine that prevents bone loss by inhibiting the process of osteoclastogenesis, reducing bone resorption. The aim of our study was to determine the influence of the rs3102735 (−163A>G), rs3134070 (−245T>G), rs207361 (−950T>C), rs7844539 (6890A>C), and rs2073618 (1181G>C) polymorphisms of the <i>OPG</i> gene on the risk of osteoporosis and osteopenia in postmenopausal Polish women. The study included 802 unrelated women (osteoporosis: <i>n</i> = 317, osteopenia: <i>n</i> = 110, controls: <i>n</i> = 375) at postmenopausal age (54.7 ± 8.6 years). Genetic analysis was performed using real-time PCR. BMD values as well as clinical and bone parameters with the tested polymorphisms were analyzed among the study population. Analysis of the <i>PPARG</i> rs1801282 variants did not show any association with the risk of osteoporosis and osteopenia. However, for the <i>OPG</i> rs207361 polymorphism, we observed a statistically significant association with the risk of osteoporosis, suggesting that the <i>OPG</i> rs207361 variant may be one of the genetic markers associated with the pathogenesis of osteoporosis. |
| first_indexed | 2024-03-08T20:59:14Z |
| format | Article |
| id | doaj.art-f793a42e0f9e4a269a983c12d3c7e906 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-08T20:59:14Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-f793a42e0f9e4a269a983c12d3c7e9062023-12-22T13:55:00ZengMDPI AGBiomedicines2227-90592023-12-011112321810.3390/biomedicines11123218Osteoprotegerin Gene as a Biomarker in the Development of Osteoporosis in Postmenopausal WomenFilip Przerwa0Izabela Uzar1Anna Bogacz2Katarzyna Kotrych3Tadeusz Sulikowski4Marlena Wolek5Adam Kamiński6Paweł Ziętek7Bogusław Czerny8Department of Pharmacology and Pharmacoeconomics, Pomeranian Medical University in Szczecin, 71-230 Szczecin, PolandDepartment of Pharmacology and Pharmacoeconomics, Pomeranian Medical University in Szczecin, 71-230 Szczecin, PolandDepartment of Personalized Medicine and Cell Therapy, Regional Blood Center, Marcelińska 44, 60-354 Poznan, PolandDepartment of General and Dental Radiology, Pomeranian Medical University in Szczecin, al. Powstańców Wielkopolskch 72, 70-111 Szczecin, PolandGeneral, Mini-Invasive and Gastroenterogical Surgery Clinic, Pomeranian Medical University in Szczecin, 71-252 Szczecin, PolandDepartment of Stem Cells and Regenerative Medicine, Institute of Natural Fibres and Medicinal Plants, Kolejowa 2, 62-064 Plewiska, PolandDepartment of Orthopaedics and Traumatology, Independent Public Clinical Hospital No. 1, Pomeranian Medical University in Szczecin, Unii Lubelskiej 1, 71-252 Szczecin, PolandDepartment of Orthopaedics, Traumatology and Orthopaedic Oncology, Pomeranian Medical University, Unii Lubelskiej 1, 71-252 Szczecin, PolandDepartment of Pharmacology and Pharmacoeconomics, Pomeranian Medical University in Szczecin, 71-230 Szczecin, PolandOsteoporosis is a multifactorial and polygenic disease caused by an imbalance between osteoclastogenesis and osteoblastogenesis, leading to a decrease in bone mineral density and the occurrence of disorders in the microarchitecture and metabolism of bone tissue. In postmenopausal women, there is a significant decrease in the production of estrogens, which play a key role in maintaining proper bone mineral density. Estrogens have an inhibitory effect on the development and activity of osteoclasts by reducing the synthesis of pro-resorption cytokines and stimulating the expression of osteoprotegerin (OPG). Osteoprotegerin is a cytokine that prevents bone loss by inhibiting the process of osteoclastogenesis, reducing bone resorption. The aim of our study was to determine the influence of the rs3102735 (−163A>G), rs3134070 (−245T>G), rs207361 (−950T>C), rs7844539 (6890A>C), and rs2073618 (1181G>C) polymorphisms of the <i>OPG</i> gene on the risk of osteoporosis and osteopenia in postmenopausal Polish women. The study included 802 unrelated women (osteoporosis: <i>n</i> = 317, osteopenia: <i>n</i> = 110, controls: <i>n</i> = 375) at postmenopausal age (54.7 ± 8.6 years). Genetic analysis was performed using real-time PCR. BMD values as well as clinical and bone parameters with the tested polymorphisms were analyzed among the study population. Analysis of the <i>PPARG</i> rs1801282 variants did not show any association with the risk of osteoporosis and osteopenia. However, for the <i>OPG</i> rs207361 polymorphism, we observed a statistically significant association with the risk of osteoporosis, suggesting that the <i>OPG</i> rs207361 variant may be one of the genetic markers associated with the pathogenesis of osteoporosis.https://www.mdpi.com/2227-9059/11/12/3218osteoporosisgene <i>OPG</i>polymorphismpostmenopausal womenosteoprotegerin |
| spellingShingle | Filip Przerwa Izabela Uzar Anna Bogacz Katarzyna Kotrych Tadeusz Sulikowski Marlena Wolek Adam Kamiński Paweł Ziętek Bogusław Czerny Osteoprotegerin Gene as a Biomarker in the Development of Osteoporosis in Postmenopausal Women Biomedicines osteoporosis gene <i>OPG</i> polymorphism postmenopausal women osteoprotegerin |
| title | Osteoprotegerin Gene as a Biomarker in the Development of Osteoporosis in Postmenopausal Women |
| title_full | Osteoprotegerin Gene as a Biomarker in the Development of Osteoporosis in Postmenopausal Women |
| title_fullStr | Osteoprotegerin Gene as a Biomarker in the Development of Osteoporosis in Postmenopausal Women |
| title_full_unstemmed | Osteoprotegerin Gene as a Biomarker in the Development of Osteoporosis in Postmenopausal Women |
| title_short | Osteoprotegerin Gene as a Biomarker in the Development of Osteoporosis in Postmenopausal Women |
| title_sort | osteoprotegerin gene as a biomarker in the development of osteoporosis in postmenopausal women |
| topic | osteoporosis gene <i>OPG</i> polymorphism postmenopausal women osteoprotegerin |
| url | https://www.mdpi.com/2227-9059/11/12/3218 |
| work_keys_str_mv | AT filipprzerwa osteoprotegeringeneasabiomarkerinthedevelopmentofosteoporosisinpostmenopausalwomen AT izabelauzar osteoprotegeringeneasabiomarkerinthedevelopmentofosteoporosisinpostmenopausalwomen AT annabogacz osteoprotegeringeneasabiomarkerinthedevelopmentofosteoporosisinpostmenopausalwomen AT katarzynakotrych osteoprotegeringeneasabiomarkerinthedevelopmentofosteoporosisinpostmenopausalwomen AT tadeuszsulikowski osteoprotegeringeneasabiomarkerinthedevelopmentofosteoporosisinpostmenopausalwomen AT marlenawolek osteoprotegeringeneasabiomarkerinthedevelopmentofosteoporosisinpostmenopausalwomen AT adamkaminski osteoprotegeringeneasabiomarkerinthedevelopmentofosteoporosisinpostmenopausalwomen AT pawełzietek osteoprotegeringeneasabiomarkerinthedevelopmentofosteoporosisinpostmenopausalwomen AT bogusławczerny osteoprotegeringeneasabiomarkerinthedevelopmentofosteoporosisinpostmenopausalwomen |